MTAP and myxofibrosarcoma: The disabled methionine salvage in MTAP-inactivated myxofibrosarcomas renders this aggressive tumor subset a tumor-specific metabolic feature for use in L-alanosine therapy, which targets adenylosuccinate synthetase to abolish de novo AMP synthesis from IMP [13, 14, 30].